Eli Lilly (LLY)
(Delayed Data from NYSE)
$891.07 USD
+6.59 (0.75%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $891.10 +0.03 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$891.07 USD
+6.59 (0.75%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $891.10 +0.03 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth B Momentum F VGM
Zacks News
Earnings Preview: Eli Lilly (LLY) Q2 Earnings Expected to Decline
by Zacks Equity Research
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eli Lilly (LLY) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
NuCana Initiates Dosing in Phase I Study for Solid Tumors
by Zacks Equity Research
NuCana (NCNA) doses the first patient in a phase I study on NUC-7738, which is being evaluated for the treatment of advanced solid tumors.
AC Immune Initiates Phase I Study for Alzheimer's Disease
by Zacks Equity Research
AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.
Alkermes to Include Bipolar I Disorder in ALKS 3831 NDA
by Zacks Equity Research
Alkermes (ALKS) plans to expand the NDA for ALKS 3831 to include the treatment of bipolar I disorder in addition to the treatment for schizophrenia.
Drug Pricing Woes Linger on Repealing Drug Rebate Proposal
by Zacks Equity Research
Investors' skepticism runs rife as Trump drops the drug rebate proposal, pushing drugmakers to take center stage with regard to the controversial drug pricing issue.
4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal
by Christopher Vargas
In early May, President Donald Trump announced that he would be requiring Big Pharma to list the prices of their drugs in their TV advertisements.
The Zacks Analyst Blog Highlights: Bank of America, Eli Lilly, Boston Scientific, Schwab and Advanced Micro Devices
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bank of America, Eli Lilly, Boston Scientific, Schwab and Advanced Micro Devices
Court Ruling Topples Trump Order, No Price Display in TV Ads
by Zacks Equity Research
The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.
Top Stock Reports for Bank of America, Eli Lilly & Boston Scientific
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Eli Lilly (LLY) and Boston Scientific (BSX).
Incyte Out-Licenses INCMGA0012 Rights in China to Zai Lab
by Zacks Equity Research
Incyte (INCY) inks a licensing deal with Zai Lab to develop and commercialize INCMGA0012 for hematology and oncology indications in Greater China.
Will the Pharma Space Witness More Mega-Merger Deals in 2H?
by Kinjel Shah
After two mega-mergers, Bristol-Myers/Celgene and AbbVie/Allergan, in first half of 2019, it remains to be seen if more such deals are in store for the second half.
Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Pfizer's Eucrisa Proves Safety in Kids with Atopic Dermatitis
by Zacks Equity Research
Pfizer's (PFE) Eucrisa ointment is found safe in a late-stage label expansion study for treating mild to moderate atopic dermatitis in minors aged 3 months to 2 years.
Gilead to Submit NDA for Inflammation Drug Filgotinib in '19
by Zacks Equity Research
Gilead (GILD) is planning to submit regulatory application to the FDA seeking approval for filgotinib as a treatment for rheumatoid arthritis.
Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger
by Kinjel Shah
AbbVie (ABBV) announces definitive deal to buy Allergan (AGN). Bristol-Myers (BMY) set to sell Celgene's Otezla to complete the impending merger.
Lilly's Study on Higher Doses of Trulicity Meets Endpoint
by Zacks Equity Research
Lilly's (LLY) phase III study evaluating higher doses of Trulicity meets primary and secondary efficacy endpoints.
Axsome Initiates Phase III Study on Depression Candidate
by Zacks Equity Research
Axsome (AXSM) initiates phase III GEMINI study of AXS-05 for the treatment of major depressive disorder.
Why These Innovative Biotech ETFs Are Soaring
by Neena Mishra
Strong M&A activity has sent shares of many small, innovative biotech companies surging
Allergan's Botox Wins FDA Nod for Upper Limb Spasticity in Kids
by Zacks Equity Research
Allergan's (AGN) Botox gets FDA approval for the 10th therapeutic indication, upper limb spasticity in pediatric patients, in the age group of 2 to 17 years.
Allergan Up As Analyst Statement Sparks Business Split Rumors
by Zacks Equity Research
Allergan's (AGN) shares up following a conference call with one of the company's executives, which led an analyst to believe that a split of the company's business is in the cards.
Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio
by Zacks Equity Research
Pfizer (PFE) offers $48 per share to buy Array BioPharma and strengthen its cancer portfolio.
Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients
by Zacks Equity Research
Novo Nordisk's (NVO) Victoza gets FDA approval for the treatment of pediatric patients aged 10 years or older with type II diabetes.
Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
by Kinjel Shah
Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.